Impact of C-reactive protein on in-stent restenosis: A meta-analysis

Texas Heart Institute Journal

Volumn 37, Issue 1, 2010, Pages 49-57

  Li, Jian Jun ^a   Ren, Yi ^b   Chen, Ke Ji ^c   Yeung, Alan C ^d   Xu, Bo ^a   Ruan, Xin Min ^b   Yang, Yue Jin ^a   Chen, Ji Lin ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^c XIYUAN HOSPITAL   (China)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angina pectoris epidemiology; Angioplasty, transluminal, percutaneous coronary; Biological markers blood; C reactive protein analysis metabolism; Clinical trials as topic; Coronary artery disease etiology physiopathology; Coronary restenosis etiology pathology prevention control; Inflammation complications; Risk factors; Stents adverse effects

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CORONARY STENT; EVIDENCE BASED MEDICINE; HUMAN; IN-STENT RESTENOSIS; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; STENTS; TREATMENT OUTCOME; UP-REGULATION;

EID: 77950410155     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Li JJ. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J (Engl) 2005;118(21):1817-26.
2. Maseri A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. N Engl J Med 1997; 336(14):1014-6.
3. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999;340(2):115-26.
4. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004;62(4):499-506.
5. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003;163(11):1323-8.
6. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000;284(14):1828-36.
7. Li JJ, Xu B, Yang YJ, Ma WH, Chen JL, Qiao SB, et al. A comparison of angiographic and clinical outcomes after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis. Chin Med J (Engl) 2006;119(13):1059-64.
8. Versaci F, Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 2004;15(6):307-11.
9. Li JJ, Nie SP, Zhang CY, Gao Z, Zheng X, Guo YL. Is inflammation a contributor for coronary stent restenosis? Med Hypotheses 2007;68(5):945-51.
10. Gaspardone A, Versaci F. Coronary stenting and inflammation. Am J Cardiol 2005;96(12A):65L-70L.
11. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22(11):1769-76.
12. Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006;97 (10):1473-7.
13. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96(10):1384-8.
14. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84(1):83-7.
15. Bhatt DL. Inflammation and restenosis: is there a link? Am Heart J 2004;147(6):945-7.
16. Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis 2005;19(2):87-92.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008-12.
18. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5(1):13.
19. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49(15):1642-8.
20. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49(20):2003-9.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-58.
22. Angioi M, Abdelmouttaleb I, Rodriguez RM, Aimone-Gastin I, Adjalla C, Gueant JL, Danchin N. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol 2001;87(10):1189-93; A4.
23. Gomma AH, Hirschfield GM, Gallimore JR Jr, Lowe GD, Pepys MB, Fox KM. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004;147(6):1071-7.
24. Turker S, Guneri S, Akdeniz B, Ozcan MA, Baris N, Badak O, et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2006;97(2):198-202.
25. Skowasch D, Jabs A, Andrie R, Luderitz B, Bauriedel G. Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein. Heart 2005;91(4):535-6.
26. Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 2004;25(12): 1029-35.
27. Yip HK, Hung WC, Yang CH, Chen YH, Cheng CI, Chen SM, Yeh KH. Serum concentrations of high-sensitivity Creactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. Circ J 2005;69(10):1202-7.
28. Karaca I, Aydin K, Yavuzkir M, Ilkay E, Akbulut M, Isik A, Arslan N. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. J Int Med Res 2005;33(4):389-96.
29. Naumov VG, Sumarokov AB, Ezhov MV, Aleksandrova EN, Novikov AA, Raimbekova IR, et al. Markers of chronic inflammation in patients with ischemic heart disease with instent restenosis [in Russian]. Kardiologiia 2005;45(1):14-7.
30. Qi X, Li S, Li J. The prognostic value of IL-8 for cardiac events and restenosis in patients with coronary heart diseases after percutaneous coronary intervention. Jpn Heart J 2003;44(5): 623-32.
31. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003;89(2): 218-24.
32. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39(2):183-93.
33. Karthikeyan G, Bhargava B. Prevention of restenosis after coronary angioplasty. Curr Opin Cardiol 2004;19(5):500-9.
34. Li JJ. Inflammatory response, drug-eluting stent and restenosis. Chin Med J (Engl) 2008;121(6):566-72.
35. Aggarwal A, Blum A, Schneider DJ, Sobel BE, Dauerman HL. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 2004;15(8): 471-5.
36. Gach O, Biemar C, Nys M, Deby-Dupont G, Chapelle JP, Deby C, et al. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron Artery Dis 2005;16(1):59-65.
37. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003;107(13):1757-63.
38. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007;195(2):374-8.
39. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21(14):1152-8.
40. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98(22):2370-6.
41. Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE. Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions. Am Heart J 1998;136(2):357-61.
42. Saleh N, Svane B, Jensen J, Hansson LO, Nordin M, Tornvall P. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 2005;149(5):876-82.
43. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34(5):1512-21.
44. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med 2001;20(23):3625-33.
45. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45(12):2136-41.
46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109):629-34.